

S 1523

Drug Price Transparency Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 29, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Apr 29, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/1523>

Sponsor

Name: Sen. Braun, Mike [R-IN]

Party: Republican • **State:** IN • **Chamber:** Senate

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Hyde-Smith, Cindy [R-MS]	R · MS		Apr 29, 2021
Sen. Marshall, Roger [R-KS]	R · KS		Aug 3, 2021

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 29, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 29, 2021)

Drug Price Transparency Act of 2021

This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws.

Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.

Actions Timeline

- **Apr 29, 2021:** Introduced in Senate
- **Apr 29, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.